Liver-specific transcriptional machinery via apoE-AAT promoter controlling viral Glycoprotein H

The liver-specific transcriptional machinery refers to the set of endogenous transcription factors, such as hepatocyte nuclear factors (HNFs) and C/EBP, that selectively drive gene expression in the liver. In the context of the Liver-Cancer-Specific Oncolytic Virus (LCSOV), this machinery is exploited to drive the expression of the essential viral Glycoprotein H (gH) via a chimeric apoE-AAT promoter. This promoter combines the Apolipoprotein E (apoE) hepatic control region with the human Alpha-1 antitrypsin (AAT) promoter to achieve high-level, liver-specific transgene expression. By placing gH under this control, the virus is restricted to replicating in cells of hepatic origin, specifically targeting hepatocellular carcinoma (HCC) cells. This transcriptional targeting is often supplemented with post-transcriptional control using microRNA target sites (e.g., for miR-122) to ensure that viral replication is suppressed in healthy hepatocytes while remaining active in cancer cells. This dual-control strategy represents a sophisticated approach to oncolytic virotherapy, aiming to maximize anti-tumor efficacy while minimizing off-target effects in the liver.

Other names

apoE-AAT promoter-driven gH expression systemLCSOV regulatory machineryLiver-specific promoter systemHepatic transcriptional machinery

The oncolytic virus (LCSOV) is engineered such that the essential viral gene Glycoprotein H (gH) is under the control of the liver-specific apoE-AAT promoter. This ensures that the virus can only replicate in cells containing the liver-specific transcriptional machinery (hepatocytes and HCC cells). To further restrict replication to cancer cells, miRNA target sites (e.g., for miR-122) are often included in the 3'UTR of gH to silence expression in normal liver cells where those miRNAs are abundant.